Two Hepatitis C Drugs Carry Risk of Liver Injury, FDA Warns
November 13, 2015 | Strategic Insights for Ambulatory Care
The use of two hepatitis C drugs (Viekira Pak and Technivie) is associated with a serious risk of liver injury, states an October 22, 2015, drug safety communication from the U.S. Food and Drug Administration (FDA). Liver injury in patients taking the drug was reported as soon as one to four weeks after starting treatment and predominately found in patients who already had underlying advanced liver disease. FDA warns that patients should not stop taking the drugs without consulting their provider because stopping the medication may lead to resistance to other hepatitis C medications.